KMD 3213: KAD 3213, silodosin.
KMD 3213 [silodosin, KAD 3213] is an orally active alpha(1)-adrenoceptor antagonist under development with Kissei (Japan) for the treatment of dysuria associated with benign prostatic hyperplasia (BPH). Daiichi Pharmaceutical and Kissei are conducting phase III trials in Japan, while Kissei's US subsidiary, Kissei Pharma USA Inc., has completed early phase II trials with favourable results for the treatment of dysuria associated with benign prostatic hyperplasia (BPH). Kissei expects to file an NDA application in Japan in July 2004. Daiichi is also preparing a phase I trial in China with this compound for the treatment of dysuria associated with benign prostatic hyperplasia. According to Kissei's 2003 Annual Report, they are currently preparing to license out the development and marketing rights for KMD 3213 in Europe and North America. In March 2002, Daiichi predicted that KMD 3213 has the potential to reach peak sales of approximately 10 billion Japanese yen.
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000818:Animals; D015507:Drugs, Investigational / Q000627:therapeutic use*; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008297:Male; D011470:Prostatic Hyperplasia / Q000150:complications / Q000188:drug therapy; D014555:Urination Disorders / Q000188:drug therapy* / Q000209:etiology
D000317:Adrenergic alpha-Antagonists; D015507:Drugs, Investigational; D007211:Indoles; C095285:silodosin